A norovirus vaccine based on the mRNA technology that helped to defeat Covid will be trialled in the UK for the first time, ...

It is hoped a study will show the jab is effective against the highly infectious disease which puts the NHS under "huge ...

Wes Streeting said the virus places the health service under 'huge strain' every winter and costs taxpayers around ...

In one of our recent articles about 10 High Growth Non-Tech Stocks That Are Profitable in 2024, we talked about how the US ...

A trial in the UK will see a norovirus given to patients with the Health Secretary hoping it will cut the “burden on the NHS”.

The new mRNA vaccine from Moderna will enter final stages of testing within the next two weeks, with results so far showing ...

He said: “The UK is leading the way to develop a world-first vaccine for this vomiting bug, starting with this innovative ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

On Monday, Moderna Inc (MRNA) stock saw a decline, ending the day at $53.8 which represents a decrease of $-0.30 or -0.55% from the prior close of $54.1. The stock opened at $53.82 and touched a low ...

Looking at options history for Moderna MRNA we detected 21 trades. If we consider the specifics of each trade, it is accurate ...

Based in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a leading biotechnology company that develops messenger RNA (mRNA) ...